Exbio — About exbio — Blog — RPSA as a carcinoma marker

RPSA as a carcinoma marker

The mous

e monoclonal antibody RP-01 recognizes RPSA, a ribosomal component with diagnostic application*.

Ribosomal protein SA (RPSA) is a multi-functional protein, that is an important component of 40S ribosomal subunit, and binds to lamin.

Higher expression of RPSA is characteristic for many carcinomas, and correlates with their invasivity and metastatic potential.

It has also been described, that RPSA interacts with amyloid beta peptide during Alzheimer´s disease.

Antigen synonyms: Colon carcinoma lamin-binding protein, multidrug resistance-associated protein, lamin receptor 1, LBP, p40, 67LR, ICAS, lamR, 37LRP, LAMBR, LAMR1, NEM/1CHD4

Currently available formats:
Purified 11-829-C100
Alexa Fluor® 488 A4-829-C100

Applications:
Western Blotting, Immunocytochemistry, Flow Cytometry

Would you like to have it in other formates? Are you interested in BULK amount? Let us know!

Contact: info@exbio.cz

*The product has regulatory status RUO, thus Research-Use-Only, but within this application it has a diagnostic potential. Please do not misinterpret it as if the product was certified as IVD.

Latest Blog Entries

1/9/2020

The mouse monoclonal antibody JOVI.1, recognizing an extracellular epitope on TCR Cbeta1 (TRBC1), is suitable for flow cytometry, immunoprecipitation, and immunohistochemistry (frozen sections). It is popular as a tool for analysis of T cell-mediated diseases.

CD71 improves delineation of PNH type III, PNH type II, and normal immature RBCS in patients with pa

25/8/2020

We are proud to inform you that in March 2020 in Cytometry B (Clinical cytometry) a paper was released having one of our colleagues from EXBIO Praha team Miro Benko (Director, Product Development Department) as a co-author.

Elimination of radioresistant cancer cells using UniCAR T cell immunotherapy targeted to EGFR and CD

15/7/2020

Recently developed strategy for prevention of cancer relapse due to acquired radioresistance may be based on immunotherapies. One promising approach is based on genetically modified T cells expressing chimeric antigen receptors (CAR).